Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
accredited, ahead, Asia, Assertio, assignee, backlog, basic, Bausch, build, capture, center, chargeback, cloud, condensed, consignment, content, conventional, costlier, cotransporter, Denko, differential, disaggregated, distinct, exact, expertise, extremely, facilitate, factor, FDII, filer, fluid, freight, furlough, hinder, hire, implicate, indefinitely, inseverable, Interface, internationally, leadership, legacy, margin, motivate, noncurrent, nonexclusive, Nonrecurring, Northern, opportunistic, outbound, path, payer, PDLIH, permanent, permanently, PES, phacoemulsification, PID, portal, post, Prasco, predetermined, prepaid, principle, proven, reached, reliant, repriced, reversionary, shareholder, shipment, software, Sun, ultrasonic, unaware, unbilled, unincorporated, unsatisfied, unwound, web, wrote
Removed:
absolute, APIC, carryback, communicated, conceived, DC, dealer, declined, deduction, efficiently, encoding, evenly, exchanged, Finally, forfeiture, history, humanizing, intrinsic, issuable, light, Michigan, netting, nonstatutory, occasion, OCI, operated, outlined, PDLI, placement, polynucleotide, pool, refine, representing, Room, serve, slightly, Street, suitable, targeting, tendered, title, true, underlie, University, valve, VWAP, Washington, wholly, wide
Filing tables
Filing exhibits
Related press release
Associated PDLI transcripts
PDLI similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-36708, 333-122760, 333-123958, 333-128644 and 333-211970) and on Form S-8 (No. 333-87957, 333-68314, 333-104170, 333-125906, 333-145262, 333-220370, 333-220435 and 333-225534) of PDL Biopharma, Inc., of our report dated March 14, 2019 relating to the consolidated financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
San Francisco, California
March 14, 2019